Metformin-The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug

Current Topics in Medicinal Chemistry

Volumn 16, Issue 19, 2016, Pages 2223-2230

  Tomczynska, Malgorzata ^a   Bijak, Michal ^a   Saluk, Joanna ^a,b  

^a UNIVERSITY OF LODZ   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Autoimmune diseases; Central nervous system; Inflammation; Metformin; Oxidative stress; Proinflammatory cytokines

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT; ANTIOXIDANT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CONNECTIVE TISSUE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG REPOSITIONING; DYSLIPIDEMIA; HUMAN; METABOLIC DISORDER; AUTOIMMUNE DISEASES; CLINICAL TRIAL (TOPIC); PROCEDURES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DRUG REPOSITIONING; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 84975721670     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160216152324     Document Type: Article

References (75)

1. Brod, S.A. Unregulated inflammation shortens human functional longevity. Inflamm. Res., 2000, 49, 561-570.
2. Berlett, B.S.; Stadtman, E.R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem., 1997, 272, 20313-20316.
3. Stadtman, E.R.; Levine, R.L. Protein oxidation. Ann. N. Y. Acad. Sci., 2000, 899, 191-208.
4. Stadtman, E.R.; Levine, R.L. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino. Acids, 2003, 25, 207-218.
5. Zou, M.H.; Kirkpatrick, S.S.; Davis, B.J.; Nelson, J.S.; Wiles, W.G.; Schlattner, U.; Neumann, D.; Brownlee, M.; Freeman, M.B.; Goldman, M.H. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J. Biol. Chem., 2004, 279, 43940-43951.
6. Bailey, C.J.; Turner, R.C. Metformin. N. Engl. J. Med., 1996, 334, 574-579.
7. Lipska, K.J.; Bailey, J.C.; Inzucchi, S.E. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes. Care., 2011, 34, 1431-1437.
8. Labuzek, K.; Gabryel, B.; Okopien, B. Metformin as a key to alternative activation of microglia? Postepy Hig. Med. Dosw., 2014, 68, 247-257.
9. Dunn, C.J.; Peters, D.H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs, 1995, 49, 721-749.
10. Wilcock, C.; Bailey, C.J. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J. Pharm. Pharmacol., 1991, 43, 120-121.
11. Otsuka, M.; Matsumoto, T.; Morimoto, R.; Arioka, S.; Omote, H.; Moriyama, Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 17923-17928.
12. Shu, Y.; Brown, C.; Castro, R.A.; Shi, R.J.; Lin, E.T.; Owen, R.P.; Sheardown, S.A.; Yue, L.; Burchard, E.G.; Brett, C.M.; Giacomini, K.M. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther., 2008, 83, 273-280.
13. Song, I.S.; Shin, H.J.; Shim, E.J.; Jung, I.S.; Kim, W.Y.; Shon, J.H.; Shin, J.G. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther., 2008, 84, 559-562.
14. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108, 1167-1174.
15. Hundal, R.S.; Krssak, M.; Dufour, S.; Laurent, D.; Lebon, V.; Chandramouli, V.; Inzucchi, S.E.; Schumann, W.C.; Petersen, K.F.; Landau, B.R.; Shulman, G.I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49, 2063-2069.
16. Kirpichnikov, D.; McFarlane, S.I.; Sowers, J.R. Metformin: an update. Ann. Intern. Med., 2002, 137, 25-33.
17. Stumvoll, M.; Nurjhan, N.; Perriello, G.; Gerich, J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med., 1995, 333, 550-554.
18. Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J., 2000, 348, 607-614.
19. Gunton, J.E.; Delhanty, P.J.; Takahashi, S.; Baxter, R.C. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J. Clin. Endocrinol. Metab., 2003, 88, 1323-1332.
20. Abbasi, F.; Carantoni, M.; Chen, Y.D.; Reaven, G.M. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care, 1998, 21, 1301-1305.
21. Dresner, A.; Laurent, D.; Marcucci, M.; Griffin, M.E.; Dufour, S.; Cline, G.W.; Slezak, L.A.; Andersen, D.K.; Hundal, R.S.; Rothman, D.L.; Petersen, K.F.; Shulman, G.I. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest., 1999, 103, 253-259.
22. Grzybowska, M.; Bober, J.; Olszewska, M. Metformin-mechanisms of action and use for the treatment of type 2 diabetes mellitus. Postepy Hig. Med. Dosw., 2011, 65, 277-285.
23. Marfella, R.; Acampora, R.; Verrazzo, G.; Ziccardi, P.; De, R.N.; Giunta, R.; Giugliano, D. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care, 1996, 19, 934-939.
24. Mather, K.J.; Verma, S.; Anderson, T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol., 2001, 37, 1344-1350.
25. Ruderman, N.B.; Cacicedo, J.M.; Itani, S.; Yagihashi, N.; Saha, A.K.; Ye, J.M.; Chen, K.; Zou, M.; Carling, D.; Boden, G.; Cohen, R.A.; Keaney, J.; Kraegen, E.W.; Ido, Y. Malonyl-CoA and AMPactivated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem. Soc. Trans., 2003, 31, 202-206.
26. Musi, N.; Hirshman, M.F.; Nygren, J.; Svanfeldt, M.; Bavenholm, P.; Rooyackers, O.; Zhou, G.; Williamson, J.M.; Ljunqvist, O.; Efendic, S.; Moller, D.E.; Thorell, A.; Goodyear, L.J. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 2002, 51, 2074-2081.
27. Hawley, S.A.; Gadalla, A.E.; Olsen, G.S.; Hardie, D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes, 2002, 51, 2420-2425.
28. Chin, J.T.; Troke, J.J.; Kimura, N.; Itoh, S.; Wang, X.; Palmer, O.P.; Robbins, R.C.; Fischbein, M.P. A novel cardioprotective agent in cardiac transplantation: metformin activation of AMPactivated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection. Yale J. Biol. Med., 2011, 84, 423-432.
29. Hattori, Y.; Suzuki, K.; Hattori, S.; Kasai, K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMPactivated protein kinase activation in vascular endothelial cells. Hypertension, 2006, 47, 1183-1188.
30. Beckman, J.A.; Creager, M.A.; Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581.
31. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev., 2007, 87, 315-424.
32. Libby, G.; Donnelly, L.A.; Donnan, P.T.; Alessi, D.R.; Morris, A.D.; Evans, J.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 2009, 32, 1620-1625.
33. Hirsch, H.A.; Iliopoulos, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res., 2009, 69, 7507-7511.
34. Boguslawski, W.; Foerster, J.; Siedlecka, K. Cholesterol-friend or foe of the brain. Geront. Pol., 2008, 3, 160-162.
35. Scheen, A.J.; Esser, N.; Paquot, N. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes Metab., 2015, doi: 10.1016/j.diabet.2015.02.003. [Epub ahead of print]
36. Bijak, M.; Ponczek, M.; Saluk, J.; Chabielska, M.; Stepniak, J.; Nowak, P. Peroxynitrite a strong biological oxidant. Chemical News, 2012, 66, 623-636.
37. Beckman, J.S.; Chen, J.; Ischiropoulos, H.; Crow, J.P. Oxidative chemistry of peroxynitrite. Methods Enzymol., 1994, 233, 229-240.
38. Beckman, J.S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol., 1996, 9, 836-844.
39. Bijak, M.; Kolodziejczyk-Czepas, J.; Ponczek, M.B.; Saluk, J.; Nowak, P. Protective effects of grape seed extract against oxidative and nitrative damage of plasma proteins. Int. J. Biol. Macromol., 2012, 51, 183-187.
40. Nowak, P.; Olas, B.; Wachowicz, B. Oxidative stress in haemostasis. Postepy Biochem., 2010, 56, 239-247.
41. Rattan, R.; Giri, S.; Singh, A.K.; Singh, I. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem., 2005, 280, 39582-39593.
42. Salt, I.P.; Palmer, T.M. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert. Opin. Investig. Drugs, 2012, 21, 1155-1167.
43. Sospedra, M.; Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol., 2005, 23, 683-747.
44. Zamvil, S.S.; Steinman, L. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron, 2003, 38, 685-688.
45. Ermann, J.; Fathman, C.G. Autoimmune diseases: genes, bugs and failed regulation. Nat. Immunol., 2001, 2, 759-761.
46. Miller, E.; Walczak, A.; Saluk, J.; Ponczek, M.B.; Majsterek, I. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin. Biochem., 2012, 45, 26-30.
47. Miller, E.; Mrowicka, M.; Malinowska, K.; Mrowicki, J.; Saluk-Juszczak, J.; Kedziora, J. Effects of whole-body cryotherapy on a total antioxidative status and activities of antioxidative enzymes in blood of depressive multiple sclerosis patients. World J. Biol. Psychiatry, 2011, 12, 223-227.
48. Nath, N.; Khan, M.; Paintlia, M.K.; Singh, I.; Hoda, M.N.; Giri, S. Metformin attenuated the autoimmune disease of the central nerv ous system in animal models of multiple sclerosis. J. Immunol., 2009, 182, 8005-8014.
49. Caballero, A.E.; Delgado, A.; Aguilar-Salinas, C.A.; Herrera, A.N.; Castillo, J.L.; Cabrera, T.; Gomez-Perez, F.J.; Rull, J.A. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab., 2004, 89, 3943-3948.
50. De Jager, J.; Kooy, A.; Lehert, P.; Bets, D.; Wulffele, M.G.; Teerlink, T.; Scheffer, P.G.; Schalkwijk, C.G.; Donker, A.J.; Stehouwer, C.D. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med., 2005, 257, 100-109.
51. dos Santos, A.C.; Barsante, M.M.; Arantes, R.M.; Bernard, C.C.; Teixeira, M.M.; Carvalho-Tavares, J. CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis--an intravital microscopy study. J. Neuroimmunol., 2005, 162, 122-129.
52. Narender, T.; Khaliq, T.; Singh, A.B.; Joshi, M.D.; Mishra, P.; Chaturvedi, J.P.; Srivastava, A.K.; Maurya, R.; Agarwal, S.C. Synthesis of alpha-amyrin derivatives and their in vivo antihyperglycemic activity. Eur. J. Med. Chem., 2009, 44, 1215-1222.
53. Paintlia, A.S.; Paintlia, M.K.; Mohan, S.; Singh, A.K.; Singh, I. AMP-activated protein kinase signaling protects oligodendrocytes that restore central nervous system functions in an experimental autoimmune encephalomyelitis model. Am. J. Pathol., 2013, 183, 526-541.
54. Riccio P., Rossano R., Liuzzi G.M. May Diet and Dietary Supplements Improve the Wellness of Multiple Sclerosis Patients? A Molecular Approach SAGE-Hindawi Access to Research Autoimmune Diseases Volume 2010 (2010), Article ID 249842, 12 pages
55. Gabriele V. Ronnett,1,2 Santosh Ramamurthy,1 Amy M. Kleman,1 Leslie E. Landree,1 and Susan Aja3 AMPK in the Brain: Its Roles in Energy Balance and Neuroprotection J Neurochem. 2009 May; 109(Suppl 1), 17-23.
56. McInnes, I.B.; Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med., 2011, 365, 2205-2219.
57. Lee, Y.K.; Mukasa, R.; Hatton, R.D.; Weaver, C.T. Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol., 2009, 21, 274-280.
58. Indo, Y.; Takeshita, S.; Ishii, K.A.; Hoshii, T.; Aburatani, H.; Hirao, A.; Ikeda, K. Metabolic regulation of osteoclast differentiation and function. J. Bone Miner. Res., 2013, 28, 2392-2399.
59. Kang, K.Y.; Kim, Y.K.; Yi, H.; Kim, J.; Jung, H.R.; Kim, I.J.; Cho, J.H.; Park, S.H.; Kim, H.Y.; Ju, J.H. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. Int. Immunopharmacol., 2013, 16, 85-92.
60. Son, H.; Lee, J.; Lee, S.; Kim, E.; Park, M.; Kim, K.; Park, S.; Cho, M. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th/Treg balance and osteoclastogenesis. Med. in Inflam., 2014, 2014, 973986.
61. Taghavi, S.; Rokini, H.; Fatemi, S. Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrom and hypothyroidism. Diab. Vasc. Dis. Res., 2011, 8, 47-48.
62. Cortes, V.A.; Fernandez-Galilea, M. Lipodystrophies: adipose tissue disorders with severe metabolic implications. J. Physiol. Biochem., 2015, [Epub ahead of print].
63. Eren, E.; Ozkan, T.B.; Cakir, E.D.; Saglam, H.; Tarim, O. Acquired generalized lipodystrophy associated with autoimmune hepatitis and low serum C4 level. J. Clin. Res. Pediatr. Endocrinol., 2010, 2, 39-42.
64. Garg, A. Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J. Clin. Endocrinol. Metab., 2011, 96, 3313-3325.
65. Mahmood, K.; Naeem, M.; Rahimnajjad, N.A. Metformin: the hidden chronicles of a magic drug. Eur. J. Intern. Med., 2013, 24, 20-26.
66. Rojas, L.B.A.; Gomes, M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr., 2013, 5, 6.
67. Kim, S.C.; Glynn, R.J.; Liu, J.; Everett, B.M.; Goldfine, A.B. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol., 2014, 51, 1015-1023.
68. Youssef, S.; Stuve, O.; Patarroyo, J.C.; Ruiz, P.J.; Radosevich, J.L.; Hur, E.M.; Bravo, M.; Mitchell, D.J.; Sobel, R.A.; Steinman, L.; Zamvil, S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420, 78-84.
69. Paintlia, A.S.; Paintlia, M.K.; Singh, A.K.; Stanislaus, R.; Gilg, A.G.; Barbosa, E.; Singh, I. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J. Neurosci. Res., 2004, 77, 63-81.
70. Feng, X.; Han, D.; Kilaru, B.K.; Franek, B.S.; Niewold, T.B.; Reder, A.T. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch. Neurol., 2012, 69, 1303-1309.
71. Fernandez-Galaz, M.C.; Morschl, E.; Chowen, J.A.; Torres-Aleman, I.; Naftolin, F.; Garcia-Segura, L.M. Role of astroglia and insulin-like growth factor-I in gonadal hormone-dependent synaptic plasticity. Brain Res. Bull., 1997, 44, 525-531.
72. Linker, R.A.; Maurer, M.; Gaupp, S.; Martini, R.; Holtmann, B.; Giess, R.; Rieckmann, P.; Lassmann, H.; Toyka, K.V.; Sendtner, M.; Gold, R. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med., 2002, 8, 620-624.
73. Aharoni, R.; Eilam, R.; Domev, H.; Labunskay, G.; Sela, M.; Arnon, R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 19045-19050.
74. Escartin, C.; Pierre, K.; Colin, A.; Brouillet, E.; Delzescaux, T.; Guillermier, M.; Dhenain, M.; Deglon, N.; Hantraye, P.; Pellerin, L.; Bonvento, G. Activation of astrocytes by CNTF induces metabolic plasticity and increases resistance to metabolic insults. J. Neurosci., 2007, 27, 7094-7104.
75. Gomez-Pinilla, F.; Vaynman, S.; Ying, Z. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur. J. Neurosci., 2008, 28, 2278-2287.